glutamic acid and dabrafenib

glutamic acid has been researched along with dabrafenib in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Allan, RW; Drane, WE; Ivey, AM; Kaye, FJ; Mendenhall, WM1
Abedalthagafi, M; Barker, FG; Brastianos, PK; Cahill, DP; Curry, WT; Dunn, IF; Frederick, DT; Getz, G; Gill, CM; Jones, PS; Louis, DN; Nahed, BV; Nayyar, N; Panka, DJ; Romero, JM; Santagata, S; Shankar, GM; Sullivan, RJ; Taylor-Weiner, A1
Chamberlain, MC1
Benedict, JJ; DeConti, R; Gibney, GT; Gonzalez, RJ; Kudchadkar, RR; McCardle, T; Messina, JL; Sloot, S; Smalley, KS; Sondak, VK; Turner, LM; Weber, JS; Zager, JS1

Other Studies

4 other study(ies) available for glutamic acid and dabrafenib

ArticleYear
Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.
    Journal of the National Cancer Institute, 2015, Volume: 107, Issue:1

    Topics: Adult; Ameloblastoma; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Compassionate Use Trials; Glutamic Acid; Humans; Imidazoles; Lung Neoplasms; Male; Mandibular Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Oximes; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Radiography; Treatment Outcome; Valine

2015
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
    Journal of the National Cancer Institute, 2016, Volume: 108, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Craniopharyngioma; Craniotomy; Cytoreduction Surgical Procedures; Drug Administration Schedule; Glutamic Acid; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Neoplasm, Residual; Oximes; Pituitary Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Treatment Outcome; Valine

2016
Recurrent ganglioglioma in adults treated with BRAF inhibitors.
    CNS oncology, 2016, Volume: 5, Issue:1

    Topics: Adult; Brain Neoplasms; Enzyme Inhibitors; Female; Ganglioglioma; Glutamic Acid; Humans; Imidazoles; Male; Middle Aged; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Valine

2016
BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Melanoma research, 2016, Volume: 26, Issue:1

    Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Glutamic Acid; Humans; Imidazoles; Indoles; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Mutation, Missense; Neoadjuvant Therapy; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Retrospective Studies; Skin Neoplasms; Sulfonamides; Treatment Outcome; Valine; Vemurafenib

2016